How should a newly identified BRCA1 variant be evaluated in the context of an unusual family history?

How should a newly identified BRCA1 variant be evaluated in the context of an unusual family history?

• A. Assess co-segregation with disease, population frequency, in silico predictions, functional data, and consider expert genetic counseling and possible reclassification.
• B. Assess only population frequency.
• C. In silico predictions alone determine classification.
• D. Functional data is never used in classification.

Answer: (A)

Evaluating a BRCA1 variant in an unusual family history requires integrating multiple lines of evidence rather than relying on a single clue. The most informative approach combines whether the variant co-segregates with cancer in the family, how rare it is in the general population, what computational predictions suggest about its impact on BRCA1 function, and results from functional studies that test BRCA1 activity. Guidance from genetic counseling experts helps weigh these data and determine whether reclassification is warranted as new information emerges. This comprehensive, evidence-based framework is what provides a reliable assessment of the variant’s clinical significance. Relying only on population frequency misses pathogenic variants that are rare but causally linked to disease, and relying on in silico predictions alone is insufficient because these predictions are not definitive. Functional data are valuable but must be interpreted in the broader context and alongside other evidence, not used in isolation.

Evaluating a BRCA1 variant in an unusual family history requires integrating multiple lines of evidence rather than relying on a single clue. The most informative approach combines whether the variant co-segregates with cancer in the family, how rare it is in the general population, what computational predictions suggest about its impact on BRCA1 function, and results from functional studies that test BRCA1 activity. Guidance from genetic counseling experts helps weigh these data and determine whether reclassification is warranted as new information emerges. This comprehensive, evidence-based framework is what provides a reliable assessment of the variant’s clinical significance.

Relying only on population frequency misses pathogenic variants that are rare but causally linked to disease, and relying on in silico predictions alone is insufficient because these predictions are not definitive. Functional data are valuable but must be interpreted in the broader context and alongside other evidence, not used in isolation.